Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F17%3A00076202" target="_blank" >RIV/00023001:_____/17:00076202 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023761:_____/17:N0000019 RIV/00216208:11110/17:10365061 RIV/00064165:_____/17:10365061

Výsledek na webu

<a href="http://onlinelibrary.wiley.com/doi/10.1111/dom.13029/full" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/dom.13029/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dom.13029" target="_blank" >10.1111/dom.13029</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial

Popis výsledku v původním jazyce

We performed a randomized controlled trial with the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide as add-on to standard peri-operative insulin therapy in patients undergoing elective cardiac surgery. The aims of the study were to intensify peri-operative glucose control while minimizing the risk of hypoglycaemia and to evaluate the suggested cardioprotective effects of GLP-1-based treatments. A total of 38 patients with decreased left ventricular systolic function (ejection fraction &lt;= 50%) scheduled for elective coronary artery bypass grafting (CABG) were randomized to receive either exenatide or placebo in a continuous 72-hour intravenous (i.v.) infusion on top of standard peri-operative insulin therapy. While no significant difference in postoperative echocardiographic variables was found between the groups, participants receiving exenatide showed improved peri-operative glucose control as compared with the placebo group (average glycaemia 6.4 +/- 0.5 vs 7.3 +/- 0.8 mmol/L; P &lt; .001; percentage of time in target range of 4.5-6.5 mmol/L 54.8% +/- 14.5% vs 38.6% +/- 14.4%; P = .001; percentage of time above target range 39.7% +/- 13.9% vs 52.8% +/- 15.2%; P = .009) without an increased risk of hypoglycaemia (glycaemia &lt; 3.3 mmol/L: 0.10 +/- 0.32 vs 0.21 +/- 0.42 episodes per participant; P = .586). Continuous administration of i.v. exenatide in patients undergoing elective CABG could provide a safe option for intensifying the peri-operative glucose management of such patients.

Název v anglickém jazyce

Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial

Popis výsledku anglicky

We performed a randomized controlled trial with the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide as add-on to standard peri-operative insulin therapy in patients undergoing elective cardiac surgery. The aims of the study were to intensify peri-operative glucose control while minimizing the risk of hypoglycaemia and to evaluate the suggested cardioprotective effects of GLP-1-based treatments. A total of 38 patients with decreased left ventricular systolic function (ejection fraction &lt;= 50%) scheduled for elective coronary artery bypass grafting (CABG) were randomized to receive either exenatide or placebo in a continuous 72-hour intravenous (i.v.) infusion on top of standard peri-operative insulin therapy. While no significant difference in postoperative echocardiographic variables was found between the groups, participants receiving exenatide showed improved peri-operative glucose control as compared with the placebo group (average glycaemia 6.4 +/- 0.5 vs 7.3 +/- 0.8 mmol/L; P &lt; .001; percentage of time in target range of 4.5-6.5 mmol/L 54.8% +/- 14.5% vs 38.6% +/- 14.4%; P = .001; percentage of time above target range 39.7% +/- 13.9% vs 52.8% +/- 15.2%; P = .009) without an increased risk of hypoglycaemia (glycaemia &lt; 3.3 mmol/L: 0.10 +/- 0.32 vs 0.21 +/- 0.42 episodes per participant; P = .586). Continuous administration of i.v. exenatide in patients undergoing elective CABG could provide a safe option for intensifying the peri-operative glucose management of such patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

<a href="/cs/project/NV15-26854A" target="_blank" >NV15-26854A: Význam epikardiální tukové tkáně u onemocnění srdce: nové mechanizmy působení a jejich terapeutické ovlivnění</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes, obesity and metabolism

ISSN

1462-8902

e-ISSN

—

Svazek periodika

19

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

1818-1822

Kód UT WoS článku

000414514600021

EID výsledku v databázi Scopus

—